Markus L.
- Country
- Germany
- Department
- N/A
Research Overview
- Phase III Randomized, Placebo-Controlled Study of Venetoclax with Induction and Consolidation Chemotherapy in Newly Diagnosed AML or MDS-EB2 Patients
- Phase III Randomized Study of CPX-351 Versus Standard Chemotherapy in Adults with Newly Diagnosed AML and Intermediate or Adverse Genetic Risk
- Evaluation of Revumenib Combined with Azacitidine and Venetoclax in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML Patients Ineligible for Intensive Chemotherapy
Data & Insights
Has run more than one trial at 121 of 218 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in the treatment of acute myeloid leukemia (AML), with particular expertise in managing various genetic and molecular subtypes of the disease, including NPM1-mutated AML and cases with intermediate- or adverse-risk genetics.
- De novo AML
- AML with myelodysplasia-related changes
- Therapy-related AML
Additional focus includes myelodysplastic syndrome with excess blasts-2, demonstrating comprehensive expertise in myeloid disorders.
Treatment Approaches
The investigator explores innovative therapeutic strategies in hematologic oncology, including combinations of targeted therapies with established treatments for blood cancers.
- Standard intensive chemotherapy protocols
- Novel therapeutic combinations
- Treatment strategies for chemotherapy-ineligible patients
Expertise extends to developing personalized treatment approaches based on genetic and molecular profiles.
Clinical Outcomes
The investigator focuses on improving patient outcomes through evaluation of survival metrics in hematologic malignancies.
- Event-free survival assessment
- Overall survival evaluation
- Treatment response in specific genetic subtypes
Particular attention is given to outcomes in newly diagnosed patients and specific genetic subgroups.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.